2 results
Chapter 11 - Screening Informatics and Cheminformatics
- from Section Three - Basics of High-Throughput Screening
- Edited by Haian Fu, Emory University, Atlanta
-
- Book:
- Chemical Genomics
- Published online:
- 05 June 2012
- Print publication:
- 13 February 2012, pp 137-156
-
- Chapter
- Export citation
-
Summary
Chemical genomics projects generate enormous amounts of data in a relatively short period of time. A screening campaign against a single target can produce millions of data points before data refinement is performed [1]. Generated data must then be stored and crosslinked with data from other projects. Informatics plays a critical role in all high-throughput screening (HTS) campaigns because of the sheer volume of data that need to be interpreted and the speed at which data are generated.
Informatics activities during a screening campaign are traditionally split into two primary functions, screening informatics and cheminformatics [2–5], which are usually treated as two separate disciplines because of the different training and experience required. In brief, screening informatics concentrates efforts on data organization, quality control, accessibility, and visualization, whereas cheminformatics focuses on identification of dominant chemical structural scaffolds that demonstrate a biological advantage in an HTS campaign and recommendation of functional changes for structural optimization. Although there are stages during a screening campaign when screening informatics and cheminformatics work independently, for most of a campaign, close collaboration is required to provide the highest-quality information for decision-making processes. Both types of informatics utilize databases and specialized software to support experimental biologists and chemists. Importantly, the integration of chemical structure data with assay results must be maintained by both screening informatics and cheminformatics teams in order to be useful for future work. This chapter introduces basic applications of screening informatics and cheminformatics for HTS.
Chapter 1 - Harnessing the Power of Chemistry for Biology and Medicine
- from Section one - Overviews
- Edited by Haian Fu, Emory University, Atlanta
-
- Book:
- Chemical Genomics
- Published online:
- 05 June 2012
- Print publication:
- 13 February 2012, pp 3-9
-
- Chapter
- Export citation
-
Summary
Small molecule natural products and synthetic compounds have long been developed and housed by pharmaceutical companies and biotechnology firms for drug discovery. In the past, academic scientists studied important biological processes and drug targets while industry developed drugs directed to these well-studied and validated targets. Recently, two major paradigm shifts in the field of small molecule drug discovery have occurred: 1) an expanded role for academia in drug discovery, and 2) an increased focus on developing small molecules as chemical tools for basic research. Academic institutions have now moved into the arena of small molecule drug discovery by establishing various centers or institutes with high-throughput screening (HTS) and medicinal chemistry capabilities. At the same time, bioactive small molecule compounds are being identified and characterized to serve not only as drug leads but also as molecular tools, or chemical probes, to elucidate principles of biological processes. These transitions are primarily driven by several major developments: 1) Complete sequencing and analysis of the human genome and subsequent comparative and disease genomics have revealed a large number of potential new drug targets, which also provides enormous opportunities for functional investigations; 2) Advances in combinatorial chemistry have made small molecule compounds, which once were exclusively proprietary property of private sectors, commercially available to academic institutions; 3) The cost of acquiring robots for laboratory automation and informatics has been significantly reduced, thus making these essential resources accessible to academic investigators; and 4) Recognition of the tremendous potential of these unique opportunities and subsequent investment by various academic institutions and the National Institutes of Health (NIH) has catalyzed this transition from an almost exclusively industrial endeavor to an academic pursuit. Today, the concept that academic institutions have the ability to discover active small molecule compounds and use them to decipher the function of important biological processes has become a reality. These advances have greatly accelerated the development of the chemical biology field and have allowed scientists to harness the power of chemistry to elucidate biological processes and transform medicine.